Literature DB >> 20467151

Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial).

Takafumi Hiro1, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki.   

Abstract

BACKGROUND: The Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial has found that early aggressive statin therapy in patients with acute coronary syndrome (ACS) significantly reduces the plaque volume (PV) of non-culprit coronary lesions. The purpose of the present study was to evaluate clinical factors that have an impact on plaque regression using statin therapy. METHODS AND
RESULTS: Serial intravascular ultrasound observations over 8-12 months were performed in 252 ACS patients receiving pitavastatin or atorvastatin. Linear regression analysis identified the presence of diabetes mellitus (DM) and PV at baseline as inhibiting factors, and serum remnant-like particle-cholesterol level at baseline as a significant factor significantly affecting the degree of plaque regression. Significant correlation between % change of PV and low-density lipoprotein cholesterol (LDL-C) level was found in patients with DM (n=73, P<0.05, r=0.4), whereas there was no significant correlation between the 2 parameters in patients without DM (n=178).
CONCLUSIONS: The regression of coronary plaque induced by statin therapy after ACS was weaker in diabetic patients than their counterparts. Moreover, vigorous reduction of the LDL-C levels might induce a greater degree of plaque regression in ACS patients with DM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467151     DOI: 10.1253/circj.cj-09-0766

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  30 in total

1.  Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.

Authors:  Michael J Kraakman; Man Ks Lee; Annas Al-Sharea; Dragana Dragoljevic; Tessa J Barrett; Emilie Montenont; Debapriya Basu; Sarah Heywood; Helene L Kammoun; Michelle Flynn; Alexandra Whillas; Nordin Mj Hanssen; Mark A Febbraio; Erik Westein; Edward A Fisher; Jaye Chin-Dusting; Mark E Cooper; Jeffrey S Berger; Ira J Goldberg; Prabhakara R Nagareddy; Andrew J Murphy
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

2.  Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.

Authors:  Tessa J Barrett; Emilie Distel; Andrew J Murphy; Jiyuan Hu; Michael S Garshick; Yoscar Ogando; Jianhua Liu; Tomas Vaisar; Jay W Heinecke; Jeffrey S Berger; Ira J Goldberg; Edward A Fisher
Journal:  Circulation       Date:  2019-09-30       Impact factor: 29.690

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

4.  Is Total Risk Management an Answer for Better Prognosis in Diabetic Patients?

Authors:  Kenichi Sakakura
Journal:  J Atheroscler Thromb       Date:  2016-05-25       Impact factor: 4.928

Review 5.  Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk.

Authors:  Tessa J Barrett; Andrew J Murphy; Ira J Goldberg; Edward A Fisher
Journal:  Ann N Y Acad Sci       Date:  2017-08       Impact factor: 5.691

6.  Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.

Authors:  Tsuyoshi Nozue; Kazuki Fukui; Yutaka Koyama; Hiroyuki Fujii; Tomoyuki Kunishima; Hiroyuki Hikita; Kiyoshi Hibi; Akiyoshi Miyazawa; Ichiro Michishita
Journal:  Heart Vessels       Date:  2015-03-21       Impact factor: 2.037

Review 7.  It's reticulated: the liver at the heart of atherosclerosis.

Authors:  Prabhakara R Nagareddy; Sunil K Noothi; Michelle C Flynn; Andrew J Murphy
Journal:  J Endocrinol       Date:  2018-05-02       Impact factor: 4.286

8.  Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset.

Authors:  Naoko Takaoka; Kenichi Tsujita; Koichi Kaikita; Seiji Hokimoto; Kenshi Yamanaga; Naohiro Komura; Tadasuke Chitose; Takamichi Ono; Michio Mizobe; Eiji Horio; Koji Sato; Naoki Nakayama; Michiyo Saito; Satomi Iwashita; Sunao Kojima; Shinji Tayama; Seigo Sugiyama; Sunao Nakamura; Hisao Ogawa
Journal:  Heart Vessels       Date:  2013-08-28       Impact factor: 2.037

9.  Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis.

Authors:  Prabhakara R Nagareddy; Andrew J Murphy; Roslynn A Stirzaker; Yunying Hu; Shiquing Yu; Rachel G Miller; Bhama Ramkhelawon; Emilie Distel; Marit Westerterp; Li-Shin Huang; Ann Marie Schmidt; Trevor J Orchard; Edward A Fisher; Alan R Tall; Ira J Goldberg
Journal:  Cell Metab       Date:  2013-05-07       Impact factor: 27.287

10.  Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice.

Authors:  Chujun Yuan; Jiyuan Hu; Saj Parathath; Lisa Grauer; Courtney Blachford Cassella; Svetlana Bagdasarov; Ira J Goldberg; Ravichandran Ramasamy; Edward A Fisher
Journal:  Diabetes       Date:  2018-06-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.